Clinical & Pharma

The global map of Parkinson's disease is rapidly being redrawn, yet the landscape of the research dedicated to conquering it remains stubbornly fixed. A profound and widening disparity now exists between the populations most affected by this neurodegenerative condition and the focus of scientific

AstraZeneca has strategically positioned its formidable oncology portfolio as the primary engine for significant growth this year, banking on the robust and expanding demand for its cancer-fighting medicines to navigate a complex global landscape. Buoyed by a strong financial performance in 2025,

A groundbreaking multicountry genomic analysis of the bacterium Vibrio cholerae has fundamentally redefined the scientific community's understanding of how this deadly disease spreads across the vast and diverse landscapes of sub-Saharan Africa. By employing state-of-the-art whole-genome

In a move that signals a seismic shift in the relationship between public opinion and federal scientific priorities, the U.S. National Cancer Institute is now officially studying ivermectin, a drug that became one of the most polarizing symbols of the COVID-19 pandemic, as a potential cancer

The landscape of cancer treatment is continually being reshaped by leaders who can seamlessly bridge the gap between groundbreaking research and compassionate patient care. In a significant move to further this evolution, NYU Langone Health has announced the appointment of Dr. Daniel R. Gomez, a

A fundamental transformation is quietly reshaping the American pharmacy landscape, suggesting a future where the local drugstore might primarily dispense generic medications while complex, high-cost specialty drugs are delivered directly from the manufacturer to the patient's home. This emerging